Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis

International Journal of Antimicrobial Agents

Volumn 33, Issue 1, 2009, Pages 92-93

  Nam, Hae Seong ^a   Koh, Won Jung ^a   Kwon, O Jung ^a   Cho, Sang Nae ^b   Shim, Tae Sun ^c  

^a Samsung Medical Center   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CLARITHROMYCIN; CYCLOSERINE; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; STREPTOMYCIN;

ABSENCE OF SIDE EFFECTS; ADULT; ANEMIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BLOOD TRANSFUSION; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG SENSITIVITY; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HUMAN; LETTER; LUNG LOBECTOMY; MALE; MEDICAL RECORD REVIEW; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; OPTIC NERVE DISEASE; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPUTUM CULTURE; TREATMENT DURATION;

ACETAMIDES; ADULT; ANTI-INFECTIVE AGENTS; CULTURE MEDIA; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; KOREA; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 59349113030     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.06.014     Document Type: Letter

References (7)

1. Alcalá L., Ruiz-Serrano M.J., Pérez-Fernández Turégano C., García De Viedma D., Díaz-Infantes M., Marín-Arriaza M., et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother 47 (2003) 416-417
2. Fortún J., Martín-Dávila P., Navas E., Pérez-Elías M.J., Cobo J., Tato M., et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 56 (2005) 180-185
3. von der Lippe B., Sandven P., and Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)-a report of ten cases. J Infect 52 (2006) 92-96
4. Yew W.W., Chau C.H., and Wen K.H. Linezolid in the treatment of 'difficult' multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 12 (2008) 345-346
5. Park I.N., Hong S.B., Oh Y.M., Kim M.N., Lim C.M., Lee S.D., et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 58 (2006) 701-704
6. World Health Organization, Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 2006; 81:430-2.
7. Stalker D.J., Jungbluth G.L., Hopkins N.K., and Batts D.H. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 51 (2003) 1239-1246